Fig. 3: The targeted therapies of AKT3 or FGFR2 shrunk the PPLELC tumor in PDXs. | Communications Biology

Fig. 3: The targeted therapies of AKT3 or FGFR2 shrunk the PPLELC tumor in PDXs.

From: Single-cell analysis reveals transcriptomic features and therapeutic targets in primary pulmonary lymphoepithelioma-like carcinoma

Fig. 3

(a) Workflow diagram showing the processing of targeting AKT3 and FGFR2 treatments in PPLELC models. Created in BioRender. Xu, K. (2025) https://BioRender.com/p86s709. (b) Images of Xenograft tumors in each group of PDXs at the end of experiment (n = 6 per group). (c)Volume growth curves of xenograft tumor in PDXs (n = 6 per group). (d) The weight of xenograft tumors in PDXs were measured at the end of the experiment (n = 6 per group). P value was calculated using unpaired T tests. (e) Immunohistologic staining of AKT3 and phosphorylated AKT in xenograft tumors between Enzastaurin and NC groups (n = 6 per group) (top). Diagram showing the Hscore results of AKT3 and phosphorylated AKT (n = 6 per group) (below). Scale bars are 100 μm. (f) Immunohistologic staining of FGFR2 and phosphorylated FGFR in xenograft tumors between Enzastaurin and NC groups (n = 6 per group) (top). Diagram showing the Hscore results of FGFR2 and phosphorylated FGFR (n = 6 per group) (below). Scale bars are 100 μm. (g) The expression of total and phosphorylated AKT, GSK3β and P70S6K between Enzastaurin and NC group (left). The expression of total and phosphorylated of FGFR and ERK1/2 and phosphorylated FRS2 between Erdafitinib and NC group (right). NC, nonsense control. Data are presented as means ± standard deviation; *P  <  0.05, **P  <  0.01, ***P  <  0.001.

Back to article page